AC
DWTX

Armistice Capital’s Dogwood Therapeutics DWTX Stock Holding History

Armistice Capital’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.04M Sell
3,132,486
-147,514
-4% -$244K 0.06% 133
2026
Q1 		$6.92M Buy
+3,280,000
New +$9.65M 0.12% 108

Other funds holding DWTX

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Armistice Capital's DWTX Position: Q2 2026 in Review

Armistice Capital reduced its Dogwood Therapeutics (DWTX) stake by 4.5% in Q2 2026, selling an estimated $244K and leaving 3,132,486 shares worth $5.04M. The position accounts for 0.06% of the portfolio, ranked #133.

Armistice Capital first reported a position in DWTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.92M in Q1 2026. 15 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

  • Armistice Capital held 3,132,486 shares of Dogwood Therapeutics worth $5.04M as of Q2 2026.
  • Armistice Capital sold 147,514 Dogwood Therapeutics shares in Q2 2026, an estimated $244K.
  • Dogwood Therapeutics made up 0.06% of Armistice Capital's portfolio in Q2 2026, its #133 holding.
  • Armistice Capital first reported a position in Dogwood Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Armistice Capital's Dogwood Therapeutics position peaked at $6.92M in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.